Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue

Issues

30,00 € / $42.00 / £23.00

Get Access to Full Text

Increased plasma concentrations of tumour markers in the absence of neoplasia

1 / Xavier Filella2 / Montse Alsina-Donadeu3 / Lluïsa Juan-Pereira4 / Àngels Bosch-Ferrer5 / Raül Rigo-Bonnin6 /

1Laboratory Medicine, Biological Diagnosis Department, Manresa Althaia Xarxa Assistencial de Manresa, Manresa, Catalonia, Spain

2Biochemistry and Molecular Genetics Service (CDB), Hospital Clínic, Barcelona, Catalonia, Spain

3Clinical Analysis Laboratory, CATLAB Viladecavalls, Villadecavalls, Catalonia, Spain

4Clinical Analysis Service, Sant Joan de Deu Hospital, Martorell, Catalonia, Spain

5Consorci Laboratori Intercomarcal, Igualada, Catalonia, Spain

6Clinical Laboratory, Bellvitge University Hospital, L’Hospitalet de Llobregat, Catalonia, Spain

Corresponding author: Jaume Trapé, Servei de Bioquímica, Departament de Diagnòstic Biològic, Althaia Xarxa Assistencial de Manresa, C/Dr Joan Soler 1-3, 08243 Manresa, Catalonia, Spain

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 10, Pages 1605–1620, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.694, September 2011

Publication History

Received:
2011-03-28
Accepted:
2011-07-25
Published Online:
2011-09-06

Abstract

Tumour markers are a very heterogeneous group of molecules that are generally found in very small concentrations in the plasma and serum of healthy individuals. In the process of neoplastic differentiation the cell can synthesize, release, or induce synthesis of other cells, thus increasing their concentration in plasma and serum. These substances may also increase their plasma concentration in patients without cancer due to processes that increase the release or reduce catabolism, and so give rise to false positives. An understanding of the main physiopathological processes that increase the concentrations of these substances could improve our interpretation of tumour markers and their clinical application. In this study we review the physiopathological processes that may increase the plasma concentrations of tumour markers. We performed a bibliography review in PubMed, searching for causes of false positives for the following tumour markers: α-Fetoprotein, CA 125, CA 15-3, CA 19-9, CA 72-4, carcinoembryonic antigen, CYFRA 21-1, squamous cell carcinoma, prostatic specific antigen, β2-microglobulin, choriogonadotropin (β chain), chromogranin A, neuron specific enolase, HER2-neu, progastrin releas-ing peptide, S-100, and thyroglobulin. The results favour the use of tests which can identify pathological processes that may increase tumour marker concentrations.

Keywords: benign disease; false positives; tumour markers

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
János Kappelmayer, Péter Antal-Szalmás, and Béla Nagy
Clinica Chimica Acta, 2015, Volume 438, Page 35
[2]
A. Karabulut, N. Karabulut, and M. Akbulut
Journal of Obstetrics & Gynaecology, 2015, Volume 35, Number 2, Page 215
[3]
Jaume Trapé, Pere Guiteres, Josep M. Roca, Josep Reig, Jesús Montesinos, and Josefina Franquesa
Scandinavian Journal of Clinical & Laboratory Investigation, 2014, Volume 74, Number 7, Page 653
[4]
Peppino Mirabelli and Mariarosaria Incoronato
BioMed Research International, 2013, Volume 2013, Page 1
[5]
Enikő Orosz, István Ember, Katalin Gombos, László Tóth, Ádám Tarpay, Ákos Pap, and Szabolcs Ottó
Pathology & Oncology Research, 2013, Volume 19, Number 4, Page 619
[6]
György Miklós Buzás
Orvosi Hetilap, 2013, Volume 154, Number 21, Page 810
[7]
Jaume Trapé, Rafael Molina, Francesc Sant, Jesús Montesinos, Anna Arnau, Josefina Franquesa, Rosana Blavia, Esperanza Martín, Emili Marquilles, Damià Perich, Concepción Pérez, Josep Maria Roca, Montserrat Doménech, Joan López, and Josep Miquel Badal
Tumor Biology, 2012, Volume 33, Number 5, Page 1661
[8]
Bohuslav Melichar and Mario Plebani
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 10

Comments (0)

Please log in or register to comment.